Investment Thesis
Enanta is a cash-burning pharmaceutical company with declining revenue (-3.4% YoY) and severe profitability headwinds (-70% net margin, -19.0M negative free cash flow). While the company maintains a strong balance sheet with minimal debt and $34.9M cash, its current burn rate implies only ~1.8 years of runway before requiring external capital or achieving profitability. Lacking visibility into pipeline catalysts, the deteriorating commercial performance and negative operating cash flow signal an unsustainable business model.
Strengths
- Strong balance sheet with minimal leverage (Debt/Equity 0.02x)
- Excellent liquidity position (Current Ratio 3.84x, $34.9M cash on hand)
- Pharmaceutical sector exposure with potential for pipeline-driven turnaround
Risks
- Significant annual cash burn (-$19.0M FCF) with estimated 1.8 year runway before capital constraints
- Declining revenue (-3.4% YoY) indicates loss of market traction and insufficient new product launches
- Severely unprofitable with -70% net margin and -64.6% operating margin; negative operating cash flow signals non-viable core business
- Dependent on successful clinical development and regulatory approval for viability; no evidence of near-term catalysts
Key Metrics to Watch
- Revenue growth rate return to positive territory
- Operating cash flow inflection and path to positive FCF
- Cash balance runway and any capital raise announcements
- Pipeline advancement and clinical trial readouts for key programs
Financial Metrics
Revenue
35.8M
Net Income
-25.0M
EPS (Diluted)
$-0.87
Free Cash Flow
-19.0M
Total Assets
314.7M
Cash
34.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-64.6%
Net Margin
-70.0%
ROE
-21.5%
ROA
-8.0%
FCF Margin
-53.1%
Balance Sheet & Liquidity
Current Ratio
3.84x
Quick Ratio
3.84x
Debt/Equity
0.02x
Debt/Assets
63.0%
Interest Coverage
-2.76x
Long-term Debt
2.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T07:33:13.913817 |
Data as of: 2026-03-31 |
Powered by Claude AI